Vutrisiran in Transthyretin Amyloidosis
Open Access
- 22 August 2025
- journal article
- Published by Elsevier in JACC: Advances
- Vol. 4 (9) , 102066
Abstract
No abstract availableKeywords
Funding Information
- Alnylam Pharmaceuticals Inc
This publication has 25 references indexed in Scilit:
- Eplontersen for Hereditary Transthyretin Amyloidosis With PolyneuropathyJAMA, 2023
- Therapeutic siRNA: State-of-the-Art and Future PerspectivesBioDrugs, 2022
- A Narrative Review of the Role of Transthyretin in Health and DiseaseNeurology and Therapy, 2020
- Single‐Dose Pharmacokinetics and Pharmacodynamics of Transthyretin Targeting N‐acetylgalactosamine–Small Interfering Ribonucleic Acid Conjugate, Vutrisiran, in Healthy SubjectsClinical Pharmacology & Therapeutics, 2020
- Transthyretin Amyloid CardiomyopathyJACC, 2019
- Predictors of survival stratification in patients with wild-type cardiac amyloidosisClinical Research in Cardiology, 2017
- Genotype and Phenotype of Transthyretin Cardiac AmyloidosisJACC, 2016
- Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugsHeart Failure Reviews, 2014
- Repurposing Diflunisal for Familial Amyloid PolyneuropathyJAMA, 2013
- Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: The Transthyretin Amyloidosis Cardiac Study (TRACS)American Heart Journal, 2012